Associate Professor, Department of Medicine, Division of Infectious Diseases
Duke University
Disclosure(s): Affinivax: Advisor/Consultant; Aridis: Advisor/Consultant; Basilea Pharmaceutica: Advisor/Consultant; Concert: Advisor/Consultant; Lysovant: Advisor/Consultant; NIH Antibacterial Resistance Leadership Group and the Karius Adjudication Committee: Grant/Research Support; Pfizer: Advisor/Consultant; PSI: Advisor/Consultant; Spero Therapeutics: Data Safety Monitoring Board; Staphylococcus aureus bacteraemia Network Adaptive Platform (SNAP trial): Data Safety Monitoring Board; UpToDate: Royalties
Dr. Thomas L. Holland, MD, MSc-GH, is a Professor of Infectious Diseases at Duke University and a faculty member of the Duke Clinical Research Institute. His research interests include antibacterial trials, particularly for S. aureus bacteremia and antibiotic-resistant pathogens, as well as the design and implementation of novel clinical trial endpoints including ordinal outcomes and quality of life measures. He is active in COVID clinical care and research as well as reseach in novel diagnostics.